Langhua Pharmaceutical Achieves Milestone with FDA Inspection Success
Langhua Pharmaceutical's Success in FDA Inspection
Zhejiang Langhua Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Viva Biotech Holdings, recently demonstrated its commitment to quality by successfully passing a cGMP inspection by the U.S. Food and Drug Administration (FDA). This marked the fourth time that Langhua Pharmaceutical has achieved this important milestone, further verifying the effectiveness of its quality control system.
Implications of the FDA Approval
Receiving the Establishment Inspection Report (EIR) from the FDA is significant for Langhua Pharmaceutical. The accomplishment allows the company to provide tailored research, development, and production services globally. It ensures that their facilities meet stringent FDA guidelines, and this success is a testament to their robust operational capabilities.
Broadening Service Horizons
Langhua Pharmaceutical's successful audit comes on the heels of an inspection that evaluated six critical systems including quality assurance, materials handling, production processes, packaging, labeling, equipment, and laboratory control. This comprehensive approach is designed to maintain a high standard of excellence, which is pivotal in the pharmaceutical industry.
Innovative Solutions at Langhua
As a one-stop CDMO (Contract Development and Manufacturing Organization) solution provider, Langhua Pharmaceutical specializes in the lifecycle of small molecule drugs. Their services extend from Active Pharmaceutical Ingredients (APIs) to the Finished Dosage Form (FDF), ensuring efficient, flexible, and quality-driven CDMO services are offered to pharmaceutical enterprises across the globe.
Located in multiple strategic centers, Langhua boasts over 13,000 square meters of lab space and a dedicated team of more than 700 researchers committed to advancing R&D activities. The company has successfully passed various audits and has certification from major global health authorities, thereby enhancing its credibility and capability in the market.
Long-Standing Industry Contributions
Langhua Pharmaceutical has a rich history of contributing to the launch of more than 20 new drugs in diverse therapeutic areas including oncology, diabetes, cardiovascular conditions, and HIV treatment. Their comprehensive product line showcases their commitment to creating effective healthcare solutions.
Leadership Insights
Dr. Cheney Mao, the Chairman and CEO of Viva Biotech, emphasized the significance of passing the FDA inspection. He noted that this achievement is foundational for the company’s ongoing expansion into international markets. The focus moving forward includes enhancing CDMO production capacities and integrating CRO (Contract Research Organization) and CDMO functionalities to better support global partners in drug development.
Mr. Weidong Zhang, Senior Vice President of Viva Biotech and Executive Vice President of Langhua Pharmaceutical, also shared his pride in this recognition from the FDA. He highlighted that maintaining GMP compliance is essential, and the company will persist in strengthening its quality management practices to strive for excellence in CDMO services.
About Viva Biotech
Viva Biotech, established in 2008, specializes in providing integrated services, from early-stage Structure-Based Drug R&D to commercial manufacturing. The company is dedicated to supporting global biopharmaceutical innovators, leveraging cutting-edge technology and expert knowledge. Their team excels in drug discovery and development, addressing a broad spectrum of therapeutic needs.
About Langhua Pharmaceutical
As a vital part of Viva Biotech Holdings, Zhejiang Langhua Pharmaceutical Co., Ltd. engages in extensive research and development, coupled with production, marketing, and sourcing of pharmaceutical products. It prides itself on delivering comprehensive solutions for small molecule drugs, offering partners a seamless experience throughout the drug development lifecycle.
Frequently Asked Questions
What recent achievement did Langhua Pharmaceutical attain?
Langhua Pharmaceutical successfully passed an on-site inspection by the FDA, reinforcing its quality management practices.
How many times has Langhua Pharmaceutical passed FDA inspections?
This is the fourth time Langhua Pharmaceutical has successfully passed an FDA inspection.
What services does Langhua Pharmaceutical provide?
Langhua Pharmaceutical offers CDMO services, covering operations from APIs to ready-to-use drug forms, ensuring quality throughout the drug lifecycle.
What is the role of Viva Biotech in this development?
Viva Biotech oversees the operations of Langhua Pharmaceutical, supporting it in achieving international standards for drug manufacturing.
What future initiatives are planned for Langhua Pharmaceutical?
Langhua intends to enhance its CDMO capacities and integrate its CRO services to better assist global pharmaceutical partners.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.